Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Forstpointner · SciRah

Researcher profile · Semantic Scholar

R. Forstpointner

Share profile

R. Forstpointner — researcher profile on SciRah

h-index: 19
Works: 55
Citations: 3,448

Most-cited papers

Treatment of older patients with mantle-cell lymphoma.
H. Kluin-Nelemans, E. Hoster, O. Hermine, J. Walewski +30 more
2012New England Journal of Medicine518 citations Open access
Semantic Scholar
Improvement of overall survival in advanced stage mantle cell lymphoma.
Annina Herrmann, E. Hoster, T. Zwingers, G. Brittinger +13 more
2009Journal of Clinical Oncology427 citations
Semantic Scholar
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
O. Hermine, E. Hoster, J. Walewski, A. Bosly +33 more
2016The Lancet356 citations
Semantic Scholar
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros
R. Forstpointner, M. Unterhalt, M. Dreyling, H. Böck +10 more
2006Blood356 citations Open access
Semantic Scholar
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
E. Hoster, A. Rosenwald, F. Berger, H. Bernd +24 more
2016Journal of Clinical Oncology343 citations
Semantic Scholar
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
G. Lenz, M. Dreyling, E. Schiegnitz, R. Forstpointner +12 more
2004Blood307 citations
Semantic Scholar
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
W. Hiddemann, A. Barbui, M. Canales, P. Cannell +15 more
2018Journal of Clinical Oncology198 citations Open access
Semantic Scholar
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
E. Hoster, W. Klapper, O. Hermine, H. Kluin-Nelemans +16 more
2014Journal of Clinical Oncology164 citations
Semantic Scholar
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
J. Trotman, S. Barrington, D. Belada, M. Meignan +204 more
2018The Lancet Oncology125 citations Open access
Semantic Scholar
Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
A. Grigg, P. Solal-Céligny, P. Hoskin, K. Taylor +5 more
2003Leukemia and Lymphoma115 citations
Semantic Scholar
Treatment strategies in follicular lymphomas: current status and future perspectives.
W. Hiddemann, C. Buske, M. Dreyling, O. Weigert +4 more
2005Journal of Clinical Oncology91 citations
Semantic Scholar
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
H. Stemmler, K. Gutschow, H. Sommer, M. Malekmohammadi +6 more
2001Annals of Oncology59 citations Open access
Semantic Scholar
Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.
E. Hoster, B. Metzner, R. Forstpointner, M. Pfreundschuh +10 more
200943 citations
Semantic Scholar
Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
M. Dreyling, R. Forstpointner, W. Ludwig, M. Gramatzki +6 more
200538 citations
Semantic Scholar
Metastases to the breast from rhabdomyosarcoma: appearances on MRI
C. Perlet, Harald Sittek, R. Forstpointner, M. Kessler +1 more
1999European Radiology35 citations
Semantic Scholar
R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma
J. Kluin-nelemans, E. Hoster, J. Walewski, S. Stilgenbauer +15 more
201133 citations
Semantic Scholar
Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
W. Hiddemann, R. Forstpointner, M. Dreyling, M. Gramatzki +4 more
200526 citations
Semantic Scholar
Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
M. Dreyling, R. Forstpointner, M. Gramatzki, H. Böck +7 more
2006Journal of Clinical Oncology25 citations
Semantic Scholar
Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months
C. Buske, E. Hoster, M. Dreyling, R. Forstpointner +16 more
200820 citations
Semantic Scholar
Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial
E. Hoster, H. Kluin-Nelemans, O. Hermine, J. Walewski +16 more
201717 citations
Semantic Scholar
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
C. Nickenig, M. Dreyling, E. Hoster, W. Ludwig +8 more
2006Annals of Oncology17 citations Open access
Semantic Scholar
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
Simone Ferrero, A. Pastore, Christian Scholz, R. Forstpointner +11 more
2013Leukemia15 citations
Semantic Scholar
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
W. Hiddemann, A. Barbui, Canales Albendea, P. Cannell +13 more
201712 citations Open access
Semantic Scholar
Nine Months to Progression Using Fourth-Line Liposomally Encapsulated Paclitaxel against Hepatocellular Carcinoma
M. Christopeit, G. Lenz, R. Forstpointner, K. Bartelheim +3 more
2008Chemotherapy12 citations Open access
Semantic Scholar
Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
W. Hiddemann, R. Forstpointner, M. Dreyling, M. Gramatzki +11 more
200510 citations
Semantic Scholar
Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.
M. Dreyling, R. Forstpointner, H. Boeck, R. Repp +10 more
20069 citations
Semantic Scholar
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
R. Forstpointner, A. Hänel, R. Repp, S. Hermann +8 more
2002Deutsche Medizinische Wochenschrift9 citations
Semantic Scholar
Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).
C. Buske, E. Hoster, M. Dreyling, R. Forstpointner +8 more
20098 citations
Semantic Scholar
Rituximab maintenance therapy in follicular lymphoma
R. Forstpointner, M. Dreyling
2007Current Hematologic Malignancy Reports8 citations
Semantic Scholar
Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)
C. Schmidt, A. Zoellner, V. Jurinovic, M. Sökler +14 more
2018Blood7 citations Open access
Semantic Scholar
The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)
E. Hoster, M. Unterhalt, M. Pfreundschuh, M. Hallek +11 more
20146 citations
Semantic Scholar
Primary effusion lymphoma (PEL) without effusion: a patient case report of a PEL solid variant
C. Giessen, D. Di Gioia, B. Huber, Bettina Seppi +9 more
2011Journal of Clinical Pathology6 citations Open access
Semantic Scholar
Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV
T. Fey, N. Erickson, A. Stahler, M. Muenchhoff +15 more
2022Medical Oncology5 citations Open access
Semantic Scholar
Interferon maintenance prolongs remission duration after retrospective analysis of the German Low-Grade Lymphoma Study Group (GLSG)
E. Hoster, M. Unterhalt, R. Forstpointner, M. Pfreundschuh +8 more
20115 citations
Semantic Scholar
CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG ).
C. Nickenig, M. Dreyling, E. Schiegnitz, M. Pfreundschuh +13 more
20045 citations
Semantic Scholar
RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R‐CHOP, R‐MCP, R‐FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO
E. Hoster, M. Unterhalt, M. Hänel, G. Prange-krex +17 more
20174 citations Open access
Semantic Scholar
Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?
R. Forstpointner, M. Dreyling
2011Current Hematologic Malignancy Reports4 citations
Semantic Scholar
Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) - A case series.
C. Rausch, Charlotte Schwicht, D. Doedens, R. Forstpointner +2 more
2022European Journal of Cancer3 citations
Semantic Scholar
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
C. Hirt, E. Hoster, M. Unterhalt, M. Hänel +18 more
2021HemaSphere3 citations Open access
Semantic Scholar
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
Christian Schmidt, G. Scheubeck, V. Jurinovic, M. Sökler +13 more
2025Haematologica2 citations Open access
Semantic Scholar
HIGH PFS WITH LOW INFIELD RECURRENCES AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE NODAL FOLLICULAR LYMPHOMA: FINAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)
K. Herfarth, C. Scholz, K. Hübel, S. Wirths +19 more
2025Hematological Oncology2 citations
Semantic Scholar
Rituximab maintenance after combined immuno-chemotherapy significantly prolongs duration of remission in elderly patients with mantle cell lymphoma
M. Dreyling, E. Hoster, U. Vehling-Kaiser, C. Geisler +13 more
20112 citations
Semantic Scholar
Production and properties of monoclonal antibodies against human ecto-5'-nucleotidase.
W. Gutensohn, U. Kummer, R. Forstpointner
1986Advances in Experimental Medicine and Biology2 citations
Semantic Scholar
HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)
K. Herfarth, C. Scholz, K. Hübel, S. Wirths +20 more
2023Hematological Oncology1 citations Open access
Semantic Scholar
Flotillin‐1/2 autoimmunity in a patient with marginal zone lymphoma
E. Schuh, L. Komorowski, R. Feuerecker, R. Forstpointner +2 more
20181 citations
Semantic Scholar
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma.
C. Schulz, F. Kullmann, V. Kunzmann, W. Schepp +14 more
20121 citations
Semantic Scholar
Combined immunochemotherapy (R-FCM) is superior to chemo-therapy (FCM) alone in recurrent indolent lymphoma - results of a prospective randomized comparison
W. Hiddemann, R. Forstpointner, F. Fiedler, M. Gramatzki +8 more
20011 citations
Semantic Scholar
Erratum to: “Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance”
C. Schmidt, G. Scheubeck, V. Jurinovic, M. Sökler +13 more
2025Haematologica0 citations Open access
Semantic Scholar
Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial
S. Alig, A. Pastore, V. Jurinovic, S. Häbe +24 more
2018Blood0 citations Open access
Semantic Scholar
Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomized trial of GLSG and OSHO
M. Herold, E. Hoster, M. Unterhalt, M. Hänel +17 more
20170 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Unterhalt×33
Invite
M. Unterhalt — researcher profile on SciRah
M. Dreyling×31
Invite
M. Dreyling — researcher profile on SciRah
W. Hiddemann×27
Invite
W. Hiddemann — researcher profile on SciRah
E. Hoster×21
Invite
E. Hoster — researcher profile on SciRah

×12

Invite

B. Metzner — researcher profile on SciRah

Invite

W. Klapper — researcher profile on SciRah

Invite

M. Hänel — researcher profile on SciRah

Invite

M. Hallek — researcher profile on SciRah

Invite

H. Wandt — researcher profile on SciRah

Invite

O. Hermine — researcher profile on SciRah

S. Stilgenbauer×7

Invite

S. Stilgenbauer — researcher profile on SciRah

Invite

J. Walewski — researcher profile on SciRah